The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Docetaxel-estramustine in high-risk localized prostate cancer: First results of the French Genitourinary Tumor Group phase III trial (GETUG 12).
K. Fizazi
Consultant or Advisory Role - AstraZeneca; Keocyt; Sanofi
Honoraria - AstraZeneca; Sanofi
Research Funding - AstraZeneca; Sanofi
F. Lesaunier
No relevant relationships to disclose
R. Delva
No relevant relationships to disclose
G. Gravis
Honoraria - Keocyt; Sanofi
Research Funding - Sanofi
F. Rolland
No relevant relationships to disclose
F. Priou
No relevant relationships to disclose
J. Ferrero
No relevant relationships to disclose
N. Houede
No relevant relationships to disclose
L. Mourey
No relevant relationships to disclose
C. Theodore
No relevant relationships to disclose
I. Krakowski
No relevant relationships to disclose
J. F. Berdah
No relevant relationships to disclose
M. Baciuchka
No relevant relationships to disclose
P. Kerbrat
Research Funding - Sanofi
J. Davin
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
J. Berille
No relevant relationships to disclose
M. Habibian
No relevant relationships to disclose
J. Ichante
No relevant relationships to disclose
A. Laplanche
No relevant relationships to disclose
S. Culine
Consultant or Advisory Role - Keocyt; Sanofi
Honoraria - Sanofi
Research Funding - Sanofi